PARSHALL B LYNNE 4

What Happened

• Parshall B. Lynne, a director of Foghorn Therapeutics Inc. (FHTX), was granted a derivative equity award covering 28,000 shares on 2026-06-24. The award is reported at an acquisition price of $4.08 per share for a total reported grant value of $114,240. This was an equity award (derivative grant), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-24; Filing date (Form 4): 2026-06-25.
• Grant: 28,000 derivative shares at $4.08 per share; total reported value $114,240.
• Shares owned after transaction: Not disclosed in the filing.
• Footnote: The award vests in full on the first anniversary of the grant date, subject to continued service on the board (see footnote F1).
• Timeliness: Filing appears to have been made the next day; no late-filing notation indicated.

Context

• This is a standard director equity grant used for compensation and retention. It is reported as a derivative award (not an exercised option or immediate sale), and vesting depends on continued board service. Such grants are common and do not by themselves indicate the director buying or selling stock in the open market.